A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study.
Supera stent
endovascular therapy
femoropopliteal disease
peripheral artery disease
stent
subintimal angioplasty
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
revised:
04
02
2024
received:
28
09
2023
accepted:
19
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
Complex femoropopliteal artery disease represents a challenge. The Supera stent holds the promise of improving the results of endovascular therapy for complex femoropopliteal disease. We aimed at appraising the early and long-term effectiveness of the Supera stent after successful subintimal angioplasty (SuperSUB strategy) for complex femoropopliteal lesions. We conducted a multicenter, prospective, single-arm observational study including consecutive patients at participating centers in whom Supera was implanted after successful subintimal angioplasty for complex femoropopliteal lesions. A total of 92 patients were included Femoropopliteal arteries were the most common target, and lesion length was 261 ± 102 mm. Most procedures were technically demanding, with antegrade femoral access in 35 (38%) and retrograde distal access in 55 (60%). Supera stent length was 281 ± 111 mm, with 4, 5, and 6 mm devices being most commonly used: 32 (35%), 35 (38%), and 23 (25%), respectively. Technical success was achieved in 100% of subjects, as was clinical success (per subject), whereas procedural success (per subject) was obtained in 98%. At 24 months, freedom from clinically driven target lesion revascularization was 93%, whereas primary patency was 87%. When compared with a similar historical cohort, Supera stent use appeared to be associated with a reduction in resources. Use of Supera stent after successful subintimal recanalization of complex lower limb arterial lesions yields favorable procedural results, which are maintained over follow-up, and are associated also with a favorable resource use profile.
Sections du résumé
BACKGROUND
BACKGROUND
Complex femoropopliteal artery disease represents a challenge. The Supera stent holds the promise of improving the results of endovascular therapy for complex femoropopliteal disease.
AIMS
OBJECTIVE
We aimed at appraising the early and long-term effectiveness of the Supera stent after successful subintimal angioplasty (SuperSUB strategy) for complex femoropopliteal lesions.
METHODS
METHODS
We conducted a multicenter, prospective, single-arm observational study including consecutive patients at participating centers in whom Supera was implanted after successful subintimal angioplasty for complex femoropopliteal lesions.
RESULTS
RESULTS
A total of 92 patients were included Femoropopliteal arteries were the most common target, and lesion length was 261 ± 102 mm. Most procedures were technically demanding, with antegrade femoral access in 35 (38%) and retrograde distal access in 55 (60%). Supera stent length was 281 ± 111 mm, with 4, 5, and 6 mm devices being most commonly used: 32 (35%), 35 (38%), and 23 (25%), respectively. Technical success was achieved in 100% of subjects, as was clinical success (per subject), whereas procedural success (per subject) was obtained in 98%. At 24 months, freedom from clinically driven target lesion revascularization was 93%, whereas primary patency was 87%. When compared with a similar historical cohort, Supera stent use appeared to be associated with a reduction in resources.
CONCLUSION
CONCLUSIONS
Use of Supera stent after successful subintimal recanalization of complex lower limb arterial lesions yields favorable procedural results, which are maintained over follow-up, and are associated also with a favorable resource use profile.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione Italiana Vascolare Onlus
Organisme : Società Italiana di Diagnostica Vascolare
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Shi R, Babu S. Modern approaches and innovations in the diagnosis and treatment of peripheral vascular diseases. Front Biosci (Schol Ed). 2021;13:173‐180.
Saglietto A, Manfredi R, Elia E, et al. Cardiovascular disease burden: Italian and global perspectives. Minerva Cardiol Angiol. 2021;69:231‐240.
Aru RG, Tyagi SC. Endovascular treatment of femoropopliteal arterial occlusive disease: current techniques and limitations. Semin Vasc Surg. 2022;35:180‐189.
Ferraresi R, Palena LM, Mauri G, Manzi M. Tips and tricks for a correct “endo approach”. J Cardiovasc Surg. 2013;54:685‐711.
Giannopoulos S, Armstrong EJ. Newly approved devices for endovascular treatment of femoropopliteal disease: a review of clinical evidence. Expert Rev Cardiovasc Ther. 2019;17:729‐740.
Chun JY, Markose G, Bolia A. Developments in subintimal angioplasty in the infrainguinal segment. J Cardiovasc Surg. 2010;51:213‐221.
Kokkinidis DG, Katsaros I, Jonnalagadda AK, et al. Use, safety and effectiveness of subintimal angioplasty and re‐entry devices for the treatment of femoropopliteal chronic total occlusions: a systematic review of 87 studies and 4,665 patients. Cardiovasc Revasc Med. 2020;21:34‐45.
Silveira FT, Razuk Filho Á, Saad PF, et al. Stent fractures in the superficial femoral artery: predisposing factors and their implications. J Vasc Bras. 2022;21:e20200014.
Chowdhury M, Secemsky EA. Atherectomy vs other modalities for treatment during peripheral vascular intervention. Curr Cardiol Rep. 2022;24:869‐877.
Bontinis V, Antonopoulos CN, Bontinis A, Koutsoumpelis A, Giannopoulos A, Ktenidis K. A systematic review and meta‐analysis of Supera interwoven nitinol stents for the treatment of infrainguinal peripheral arterial disease. J Cardiovasc Surg. 2022;63:137‐145.
Palena LM, Diaz‐Sandoval LJ, Sultato E, et al. Feasibility and 1‐year outcomes of subintimal revascularization with supera®stenting of long femoropopliteal occlusions in critical limb ischemia: the “Supersub” study. Catheter Cardiovasc Interv. 2017;89:910‐920.
Silvestro M, Palena LM, Manzi M, et al. Anterolateral retrograde access to the distal popliteal artery and to the tibioperoneal trunk for recanalization of femoropopliteal chronic total occlusions. J Vasc Surg. 2018;68:1824‐1832.
Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. 1995;129:146‐172.
Bosiers M, Torsello G, Gißler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12‐month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261‐269.
Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel‐eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve‐month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495‐504.
Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer‐free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve‐month safety and effectiveness results from the Zilver PTX single‐arm clinical study. J Endovasc Ther. 2011;18:613‐623.
Diaz‐Sandoval LJ. Commentary: one‐year outcomes of endovascular therapy of the femoropopliteal segment with Supera interwoven nitinol stents: mimetism, myths, or truth? J Endovasc Ther. 2020;27:66‐68.
Saratzis A, Rudarakanchana N, Patel S, et al. Interwoven nitinol stents versus drug eluting stents in the femoro‐popliteal segment: a propensity matched analysis. Eur J Vasc Endovasc Surg. 2019;58:719‐727.
Tang TY, Soon SXY, Yap CJQ, et al. Use of the helical SUPERA™ stent and Passeo‐18 Lux™ drug‐coated balloon to treat recurrent cephalic arch stenosis for dysfunctional brachiocephalic fistulas: 1 year results of the Arch V SUPERA‐LUX study. J Vasc Access. 2023;24(4):591‐598. doi:10.1177/11297298211043083
Ko YG. SFA intervention: intraluminal or subintimal? Korean. Circ J. 2018;48(8):685‐691.
Antonopoulos CN, Mylonas SN, Moulakakis KG, et al. A network meta‐analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg. 2017;65:234‐245.e11.